NICE Stock Analysis: Nice | NASDAQ
Software - Application | NASDAQ, USA | Market Cap: 6.758m USD | 12M Return: -14.7% | US6536561086 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 60.2M
EPS Trend: 90.7%
Qual. Beats: -1
Rev. Trend: 99.2%
Qual. Beats: 3
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
NICE Ltd. is an Israel-based software company that provides AI-powered cloud platforms focused on two main areas: customer engagement and financial crime and compliance. Its Customer Engagement segment offers the CXone Mpower platform, which helps organizations automate service delivery, deploy AI-driven workforce tools, and unify enterprise knowledge and customer experience data. The Financial Crime and Compliance segment delivers embedded-AI solutions for anti-money laundering, fraud prevention, and real-time financial markets compliance, including products such as NICE Actimize, X-Sight, and Xceed, alongside NICE Evidencentral for digital evidence management in the criminal justice system.
The company operates across the United States, Europe, the Middle East, Africa, and Asia Pacific, and is headquartered in Raanana, Israel. It was incorporated in 1986 and originally known as NICE-Systems Ltd. before rebranding in June 2016. As a mid-cap player in the application software sub-industry within the broader information technology sector, NICE competes in the enterprise software market, where cloud-based delivery models and AI integration have become central to vendor differentiation.
- CXone Mpower platform adoption accelerates Customer Engagement segment growth
- Financial Crime and Compliance revenue expands on rising global AML and fraud regulation
- Shift to cloud subscriptions drives recurring revenue mix and operating margin expansion
| Net Income: 426.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -0.60 > 1.0 |
| NWC/Revenue: 11.80% < 20% (prev 40.62%; Δ -28.82% < -1%) |
| CFO/TA 0.13 > 3% & CFO 674.2m > Net Income 426.8m |
| Net Debt (-270.3m) to EBITDA (856.4m): -0.32 < 3 |
| Current Ratio: 1.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.4m) vs 12m ago -6.04% < -2% |
| Gross Margin: 65.11% > 18% (prev 67.03%; Δ -1.92% > 0.5%) |
| Asset Turnover: 59.07% > 50% (prev 53.46%; Δ 5.61% > 0%) |
| Interest Coverage Ratio: 1.01k > 6 (EBIT TTM 620.3m / Interest Expense TTM 612k) |
| A: 0.07 (Total Current Assets 1.47b - Total Current Liabilities 1.10b) / Total Assets 5.12b |
| B: 0.65 (Retained Earnings 3.31b / Total Assets 5.12b) |
| C: 0.12 (EBIT TTM 620.3m / Avg Total Assets 5.22b) |
| D: 2.81 (Book Value of Equity 3.78b / Total Liabilities 1.34b) |
| Altman-Z'' = 6.33 = AAA |
| DSRI: 1.13 (Receivables 836.6m/681.0m, Revenue 3.08b/2.84b) |
| GMI: 1.03 (GM 67.03% / 65.11%) |
| AQI: 1.39 (AQ_t 0.66 / AQ_t-1 0.47) |
| SGI: 1.09 (Revenue 3.08b / 2.84b) |
| TATA: -0.05 (NI 426.8m - CFO 674.2m) / TA 5.12b) |
| Beneish M = -2.60 (Cap -4..+1) = A |
As of October 12, 2026, the stock is trading at USD 117.49 with a total of 252,597 shares traded. Over the past week, the price has changed by +3.15%, over one month by +18.83%, over three months by +20.06% and over the past year by -14.66%.
Current recommended Stop Loss: 111.80 (which is 4.8% or 1.2 ATR below the current price).
Nice has received a consensus analysts rating of 4.07. Therefore, it is recommended to buy NICE.
- StrongBuy: 6
- Buy: 3
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 132.8 | 13% |
P/E Trailing = 16.7875
P/E Forward = 9.4429
P/S = 2.1959
P/B = 1.8283
P/EG = 0.7871
Revenue TTM = 3.08b USD
EBIT TTM = 620.3m USD
EBITDA TTM = 856.4m USD
Long Term Debt = 74.2m USD (estimated: total debt 88.2m - short term 14.0m)
Short Term Debt = 14.0m USD (from shortTermDebt, last quarter)
Debt = 88.2m USD (from shortLongTermDebtTotal, last quarter) (leases 88.2m already included)
Net Debt = -270.3m USD (calculated: Debt 88.2m - CCE 358.5m)
Enterprise Value = 6.49b USD (6.76b + Debt 88.2m - CCE 358.5m)
Interest Coverage Ratio = 1.01k (Ebit TTM 620.3m / Interest Expense TTM 612k)
EV/FCF = 10.70x (Enterprise Value 6.49b / FCF TTM 606.2m)
FCF Yield = 9.34% (FCF TTM 606.2m / Enterprise Value 6.49b)
FCF Margin = 19.68% (FCF TTM 606.2m / Revenue TTM 3.08b)
Net Margin = 13.85% (Net Income TTM 426.8m / Revenue TTM 3.08b)
Gross Margin = 65.11% ((Revenue TTM 3.08b - Cost of Revenue TTM 1.07b) / Revenue TTM)
Gross Margin QoQ = 64.04% (prev 64.38%)
Tobins Q-Ratio = 1.27 (Enterprise Value 6.49b / Total Assets 5.12b)
Interest Expense / Debt = 0.69% (Interest Expense 612k / Debt 88.2m)
Taxrate = 31.14% (193.0m / 619.7m)
NOPAT = 427.2m (EBIT 620.3m * (1 - 31.14%))
Current Ratio = 1.33 (Total Current Assets 1.47b / Total Current Liabilities 1.10b)
Debt / Equity = 0.02 (Debt 88.2m / totalStockholderEquity, last quarter 3.78b)
Debt / EBITDA = -0.32 (Net Debt -270.3m / EBITDA 856.4m)
Debt / FCF = -0.45 (Net Debt -270.3m / FCF TTM 606.2m)
Total Stockholder Equity = 3.80b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.18% (Net Income 426.8m / Total Assets 5.12b)
RoE = 11.24% (Net Income TTM 426.8m / Total Stockholder Equity 3.80b)
RoCE = 16.02% (EBIT 620.3m / Capital Employed (Equity 3.80b + L.T.Debt 74.2m))
RoIC = 11.02% (NOPAT 427.2m / Invested Capital 3.88b)
WACC = 9.08% (E(6.76b)/V(6.85b) * Re(9.19%) + D(88.2m)/V(6.85b) * Rd(0.69%) * (1-Tc(0.31)))
Discount Rate = 9.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.86 | Cagr: -4.92%
[DCF] Terminal Value 71.65% ; FCFF base≈627.8m ; Y1≈587.2m ; Y5≈539.7m
[DCF] Fair Price = 134.3 (EV 7.60b - Net Debt -270.3m = Equity 7.87b / Shares 58.6m; r=9.08% [WACC]; 5y FCF grow -8.16% → 2.50% )
EPS Correlation: 90.65 | EPS CAGR: 12.28% | SUE: -2.84 | # QB: -1
Revenue Correlation: 99.19 | Revenue CAGR: 10.79% | SUE: 4.0 | # QB: 3
EPS current Quarter (2026-09-30): EPS=2.78 | Chg30d=+0.13% | Revisions=-31% | Analysts=13
EPS current Year (2026-12-31): EPS=11.17 | Chg30d=+0.03% | Revisions=+80% | GrowthEPS=-9.2% | GrowthRev=+8.0%
EPS next Year (2027-12-31): EPS=12.67 | Chg30d=+0.15% | Revisions=+50% | GrowthEPS=+13.4% | GrowthRev=+9.1%
[Analyst] Revisions Ratio: +42% (up=24, down=9)